Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Enersense International Plc's January-June 2022 Half-year Financial Report:

Enersense Internatonal PlcStock exchange release 4 August 2022 at 12:30 p.m.The challenging business environment burdened the result for the first half of the year – The company is preparing for the green transition through significant investmentsThis release is a summary of Enersense's 2022 Half-year Financial Report. The complete report is attached to this release as a pdf-file. It is also available on the company's website at www.enersense.com/investors. April–June 2022 •    Revenue EUR 59.8 million (61.6), -2,9% year-on-year •    EBITDA EUR -0.6 million (5.8), EBITDA margin

Pro VC awarded a National Teaching Fellowship

Staffordshire University’s new Pro Vice-Chancellor has been recognised with a National Teaching Fellowship for his ground-breaking work on degree apprenticeships.Professor Raheel Nawaz has recently joined Staffordshire University from Manchester Metropolitan University where he headed up their Digital Degree Apprenticeships portfolio and founded the Apprenticeships Research Unit. He is one of 54 new National Teaching fellows announced by Advance HE which celebrates and recognises individuals who have made an outstanding impact on student outcomes and the teaching profession in higher

Invitation to news conference: Kamux Corporation publishes its Half Year Financial Report for January–June on August 12, 2022

Kamux Corporation Press release 4.8.2022 at 12:00 Invitation to news conference: Kamux Corporation publishes its Half Year Financial Report for January–June on August 12, 2022 Kamux Corporation will publish its Half Year Financial Report for January–June 2022 on Friday, August 12, 2022 at approximately 9:00 EET. The report will be available at www.kamux.com after publishing. News conference for investors, analysts and media will be held on Friday, August 12, 2022 at Sanomatalo, Flik Studio Eliel, 1[st] floor, Töölönlahdenkatu 2, Helsinki at 11:00 EET in English, and at 12:00 noon

Arié and Europi acquire Lx Factory in Lisbon, from a fund managed by Keys REIM

Lx Factory has been acquired by a joint venture between the Arié Group and Europi Property Group, in an investment process managed by Bedrock Capital, for an undisclosed amount. The vendor, a fund managed by Keys REIM a French asset manager, has owned and managed Lx Factory since 2017. Arié, Europi and Bedrock intend to preserve Lx Factory’s unique identity and cultural heritage, which shall continue its mixed-use offering of office, retail and F&B while maintaining its iconic industrial look & feel. Plans are being drawn up to renovate existing spaces as well as improve the public realm

Inhalation Sciences receives landmark FDA approval for co-financing of its study to validate DissolvIt as a standard research method in the US

(Stockholm, 4 August 2022) The US FDA (Food and Drug Administration) has approved Inhalation Sciences’ proposal for a research study aiming to validate the company’s in vitro lung simulation model DissolvIt[®] as an FDA-recommended dissolution technology, and ultimately a new ‘golden standard’ for dissolution testing for inhaled drugs. The FDA will support and co-finance the study with up to 250 000 USD annually for up to two years. The study will commence in the coming months.The US FDA’s National Center for Toxicological Research has approved ISAB’s research proposal for a study aiming to

BioStock: EU gene therapy approval positive for CombiGene

Recently, PTC Therapeutics was granted marketing authorisation by the European Commission for the gene therapy Upstaza for the treatment of a rare genetic disease. This is good news for Swedish CombiGene, whose gene therapy CG01 for the treatment of epilepsy, which was outlicensed to Spark Therapeutics in the autumn of 2021, like Upstaza, is intended to be administered directly into the brain of patients. BioStock reached out to CombiGene’s CEO Jan Nilsson for a comment.Read the full interview with Jan Nilsson at biostock.se: https://www.biostock.se/en/2022/08/eu-gene-therapy-approval-

HEAT-FIT: The fire-retardant pipe jacket system by GF Piping Systems receives DNV, BV, ABS, and LR approvals

HEAT-FIT is designed to bring lightweight, corrosion-free, and efficient thermoplastic piping systems to essential applications onboard ships. Now, the fire-retardant pipe jacket system has been approved by no less than four of the leading certification societies in the maritime sector, DNV, Bureau Veritas, ABS and Lloyds Register. As a result, GF Piping Systems offers complete solutions that can be implemented throughout the entire ship and make the maritime industry more sustainable.The greenhouse gas (GHG) strategy by the International Maritime Organization (IMO) is very clear: Compared

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 142 - 4 AUGUST 2022 In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, A/S Motortramp participates by selling shares pro rata in order to maintain the current ownership of just under 32% of the shares in Dampskibsselskabet NORDEN A/S. The market will be informed accordingly – see the attached file and announcement no. 117/2022.     Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Thomas France, Investor Communications Partner, tel.: 3315 0451

Interim Report Q2 2022 - Ayima Group AB

Highlights Q2 : Apr - Jun 2022 · Total Revenue for the quarter amounted to 36.6 MSEK (40.5), a decrease of >10% from the previous year · Gross Profit increased by 1% to 20.7 MSEK (20.4) · EBITDA was 1.0 MSEK (4.7), a 78% decrease from the previous year · Net Profit after tax for the period was -1.8 MSEK (1.6) · Earnings per share (EPS) was -0.25 (0.15) YTD : Jan - Jun 2022 · Total Revenue amounted to 73.1 MSEK (77.3), a decrease of >5% from the previous year · Gross Profit increased by 3% to 42.3 MSEK (40.9) · EBITDA was 3.5 MSEK (9.7), a 64% decrease from

Change in Kesko Corporation’s Group Management Board

Kesko Corporation’s Chief Digital Officer (CDO) Anni Ronkainen has informed she’s leaving her duties in Kesko Corporation. Ronkainen has worked as CDO and member of the Group Management Board since April 2015. She’s leaving her current position at the end of September 2022. She will be available for specific assignments in the corporation until the beginning of February 2023. “Kesko Corporation and K Group have become forerunners in the trading sector in utilizing customer data and digitalisation. Anni Ronkainen has led this strategically important change in the company and executed it

Record date for dividend and prospectus for listing of Alleima AB

The 2022 Annual General Meeting of Sandvik AB decided to distribute all shares of Sandvik’s subsidiary Alleima AB to the shareholders of Sandvik and to authorize the Board of Directors of Sandvik to determine the record date for the distribution. The Board of Directors of Sandvik has today set the record date to August 29, 2022. Nasdaq Stockholm’s Listing Committee has resolved to admit Alleima shares to trading and the first day of trading in Alleima is expected to be August 31, 2022. The prospectus relating to the admission to trading of Alleima shares on Nasdaq Stockholm is expected to

Alfa Laval to acquire BunkerMetric

Alfa Laval has signed an agreement to acquire BunkerMetric, a Scandinavian software company that develops advanced decision support tools for marine bunker vessels. The acquisition is part of Alfa Laval’s strategy to expand its digital marine service offering and will be part of the recently acquired StormGeo, a global leader in weather intelligence software and decision support services. Closing of the acquisition is expected during Q3, 2022.BunkerMetric, headquartered in Denmark, supports ship operators in finding the best bunker procurement plan and improving voyage margins by using

Atlas Copco to acquire a Chinese manufacturer of on-site gas generation

Nacka, Sweden, August 4, 2022: Atlas Copco has agreed to acquire the assets of Suzhou Since Gas System Co., Ltd. (Since Gas), a China-based manufacturer of on-site gas generation equipment.Suzhou Since Gas System is a privately owned company headquartered in Suzhou, Jiangsu province, with presence throughout China. In 2021, the company had revenues of approximately 70 MCNY (MSEK 93*). The company has 80 employees. The company specializes in on-site gas generation for a broad spectrum of industries including metals, petrochemical, marine and electronics. “Suzhou Since Gas System is a

Record date for dividend and prospectus for listing of Alleima AB

The 2022 Annual General Meeting of Sandvik AB decided to distribute all shares of Sandvik’s subsidiary Alleima AB to the shareholders of Sandvik and to authorize the Board of Directors of Sandvik to determine the record date for the distribution. The Board of Directors of Sandvik has today set the record date to August 29, 2022. Nasdaq Stockholm’s Listing Committee has resolved to admit Alleima shares to trading and the first day of trading in Alleima is expected to be August 31, 2022. The prospectus relating to the admission to trading of Alleima shares on Nasdaq Stockholm is expected to

Optomed’s financial reporting in 2023

Optomed Plc Stock Exchange Release 4 August 2022 at 9.05, Helsinki Optomed’s financial reporting in 2023 Optomed Plc will release its Financial Statement Bulletin, Half-Year Financial Report and Interim Reports in 2023 as follows: · Financial Statement Bulletin for 1 January – 31 December 2022, 17 February 2023 · Interim Report for 1 January – 31 March 2023, 5 May 2023 · Half-Year Financial Report for 1 January – 30 June 2023, 4 August 2023 · Interim Report for 1 January – 30 September 2023, 3 November 2023 Annual Report 2022, which includes the company’s financial

Sweco selected as adviser for one of the world’s first energy islands

Over the next nine years, Sweco will assist the Danish Energy Agency with technical advice on Denmark’s planned energy island in the North Sea, which will be one of the first of its kind. The agreement is valued at 500 MSEK with a cap of 830 MSEK.The Danish Energy Agency’s aim for the planned energy island is to ensure that the country can harvest its unique offshore wind resources in the best possible way and establish a role model for the green transition globally. “The energy transition is one of today’s greatest and most important challenges that is creating and will continue to

Read original

NNT and Polygiene team up to create new frontline workwear uniforms for health professionals

If you work in a high-pressure environment, you want to feel fresh and comfortable. When it’s a medical or care workplace, the added advantage of clothing that’s not just smart but also inhibits bacterial growth is obvious. To tick all these boxes, NNT and Polygiene have teamed up to create a new range of protective uniforms and scrubs for health professionals.The new workwear, marketed under the Workwear Group logo, incorporates Polygiene’s innovative StayFresh™ technology. StayFresh specifically works to inhibit the growth of odor-causing bacteria in fabric. Polygiene’s principle of “Wear

Lynparza approved in EU for early breast cancer

4 August 2022 07:00 BST   Lynparza approved in the EU as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer   First and only approved medicine targetingBRCA mutations in early breast cancer  AstraZeneca and MSD’s Lynparza (olaparib) has been approved in the European Union (EU) as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2 mutations (gBRCAm), who have human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer

News conference on Kojamo’s Half-Year Report for January–June 2022 on 18 August 2022

Kojamo plc Press Release4 August 2022 at 9:00 a.m. EEST News conference on Kojamo’s Half-Year Report for January–June 2022 on 18 August 2022 Kojamo plc’s Half-Year Report for January–June 2022 will be published on Thursday, 18 August 2022 at approximately 8:00 a.m. EEST. News conference and webcast Kojamo will hold a news conference for institutional investors, analysts and media on 18 August 2022 at 10:00 a.m. at its headquarters at Mannerheimintie 168A, Helsinki, Finland. The event will be hosted by Kojamo’s CEO Jani Nieminen and CFO Erik Hjelt, and it will be held in

Herantis Pharma: Invitation to 1H 2022 Report on August 25, 2022

Herantis Pharma Plc, Press Release, August 4, 2022 at 09:00 EEST Herantis Pharma Plc("Herantis") an innovative biotech company developing new disease modifying therapies for Parkinson's disease, announced today that it will release 1H 2022 Report on Thursday August 25, 2022, at 08:00 EEST/ 07:00 CEST. Members of the Herantis’ Management team will hold a live webinar to provide more details on the 1H 2022 Report with a live Q&A session (in English) for investors, analysts, and media at 10:00 EEST / 9:00 CEST. Please join the webinar a few minutes in advance. Registration details:

Moberg Pharma and Padagis sign agreement for MOB-015 in Israel

STOCKHOLM, August 4[th], 2022, Moberg Pharma AB (OMX: MOB) has signed a distribution agreement with Padagis Israel Agencies Ltd. for MOB-015 in Israel and the Palestinian territories. Under the agreement Padagis is granted exclusive rights to market and sell MOB-015 in Israel and the Palestinian territories. Moberg Pharma assumes production and supply responsibility.Padagis will conduct registration activities in Israel, and will be marketing, distributing and selling MOB-015 in Israel and the Palestinian territories upon completion of registration. “This is the sixth commercial

UNION therapeutics announces enrollment of the first patient in ADESOS Phase 2b study of orismilast MR tablet in patients with atopic dermatitis

· ADESOS is a Phase 2b dose-finding study of orismilast modified release (MR) tablet in moderate to severe atopic dermatitis (AD) with the purpose of identifying the appropriate dose-regimen for Phase 3 studies · AD is the most common chronic inflammatory skin disease in the developed world · Orismilast is a next generation PDE4 inhibitor shown to be potent in inhibiting pathways important in AD · Orismilast MR tablet is also in development for the treatment of psoriasis and hidradenitis suppurativa (HS) Hellerup, Denmark, 4 August 2022 – UNION therapeutics A/S (UNION), a

Invitation to John Mattson’s presentation of the interim report Q2 2022 on 18 August at 11:00 am (CEST)

Invitation by John Mattson to the teleconference and webcast on Thursday 18 August at 11:00 a.m. (CEST) being held in conjunction with the publication of the company’s interim report for January-June 2022 at 8:00 a.m. (CEST) the same date.Investors, asset managers, equity analysts, the press and other stakeholders are invited to participate in the conference, where CEO Per Nilsson and CFO Mattias Lundström will present and comment on the period and result for Q2 2022. No advance notice of attendance is required. Following the presentation, it will be possible to ask questions. The

Tecnotree Corporation Financial Report for Q2 and Half Year 2022

Tecnotree Corporation Stock Exchange Release 4 Aug 2022 at 9:00 EETHealthy Order Book and Revenue Growth Second quarter (April – June 2022) · Net sales EUR 18.3 (16.7) million. · Operating result EUR 5.1 (7.6) million. · Result for the period EUR 4.0 (5.3) million. · Cash flow after investments EUR -2.1 (1.8) million. · Earnings per share EUR 0.01 (0.02). · Order book at the end of the period EUR 72.8 (55.0) million. First half (January - June 2022) · Net sales EUR 31.6 (27.9) million. · Operating result EUR 7.1 (10.6) million. · Result for the period

There are no items matching the current filter
There are no more items matching the current filter
Back to top